A study conducted by Maximilian and his group about the LAG-3 expression in human glioma suggested the diversity of immune microenvironment composition of glioma, and the combination of anti-PD-1 with LAG-3 checkpoint inhibitor is more effective at an earlier point [82]. The gene discussed is PDCD1; the disease is central nervous system cancer.